TMEM135 encodes a transmembrane protein linked to mitochondrial and peroxisomal biology. Emerging data indicate that TMEM135 participates in organelle remodeling, especially programs that coordinate mitochondrial fission and peroxisome-linked metabolic adaptation.[1][2][3] Compared with canonical neurodegeneration genes, TMEM135 evidence is still early and mechanistically focused.
The current best-supported interpretation is that TMEM135 is a stress-responsive regulator of organelle homeostasis whose dysfunction can alter bioenergetic resilience. That places it in pathways relevant to Parkinson's disease, Alzheimer's disease, and other disorders where mitochondrial quality control fails.
Recent studies describe TMEM135 as a connector between peroxisomal state and mitochondrial fission behavior.[2:1][3:1] In systems with high oxidative load, this coupling may influence fatty-acid handling, redox state, and ATP sufficiency.
Work across metabolic and sensory models suggests TMEM135 levels can shift with cellular stress and alter downstream mitochondrial phenotype, including morphology and respiration-linked programs.[1:1][4] While tissue context differs, these observations support a conserved role in organelle adaptation.
TMEM135 biology intersects conceptually with pathways involving PINK1, PRKN, MFN2, and DNM1L, though direct causal ordering remains unresolved. Current evidence supports placing TMEM135 as a modifier node rather than a master upstream controller.[1:2][2:2]
Neurodegeneration frequently includes mitochondrial fragmentation, impaired mitophagy, and altered lipid handling. Because TMEM135 is linked to mitochondrial-peroxisomal coordination, it is biologically plausible that dysregulated TMEM135 signaling could amplify neuronal stress under these conditions.[1:3][3:2]
A recent human mutation report connected TMEM135 to progressive sensorineural hearing loss, providing evidence that TMEM135 dysfunction can produce clinically meaningful neuronal phenotypes in humans.[4:1] Although this is not a classical AD/PD phenotype, it strengthens confidence that TMEM135 is not merely a cell-culture artifact.
Direct large-cohort genetic association evidence for AD/PD risk is limited.
Most neurodegeneration-specific data are inferential (pathway overlap) rather than direct intervention studies.
TMEM135 may be useful in multi-marker panels for mitochondrial/peroxisomal stress states, especially when interpreted with mitochondrial dysfunction and oxidative stress signatures.[1:4][5]
At present, TMEM135 is a pathway-level discovery target. Practical near-term strategies include:
Lobo S, Chatterjee N, Kaur H, et al. TMEM135 is a regulator of mitochondrial dynamics and physiology. Mitochondrion. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Huang T, Xu M, Li Y, et al. TMEM135 links peroxisomes to regulation of mitochondrial fission and energy homeostasis. Cell Metab. 2023. ↩︎ ↩︎ ↩︎
Park S, Reynolds A, Wang M. Roles of TMEM135 in mitochondrial and peroxisomal function with implications for age-related retinal disease. Exp Eye Res. 2024. ↩︎ ↩︎ ↩︎
Li X, Qian J, Wu Y, et al. A TMEM135 mutation causes progressive sensorineural hearing loss. Hum Mol Genet. 2025. ↩︎ ↩︎
Choi H, Reed T, Kim Y. TMEM135 deficiency improves steatosis through SIRT1-dependent metabolic reprogramming. Hepatology. 2025. ↩︎